These findings support the hypothesis in which miR-181a, MIF, and CXCR4 may contribute to immune dysregulation in CML as well as diagnostic biomarkers and promising therapeutic target. The gene discussed is MIF; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.